These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line. Takahashi Y; Nishimura T; Higuchi K; Noguchi S; Tega Y; Kurosawa T; Deguchi Y; Tomi M Pharm Res; 2018 Oct; 35(12):246. PubMed ID: 30374619 [TBL] [Abstract][Full Text] [Related]
6. Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203. Muto Y; Furihata T; Kaneko M; Higuchi K; Okunushi K; Morio H; Reien Y; Uesato M; Matsubara H; Anzai N Anticancer Res; 2019 Jan; 39(1):159-165. PubMed ID: 30591453 [TBL] [Abstract][Full Text] [Related]
7. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251 [TBL] [Abstract][Full Text] [Related]
8. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. Maimaiti M; Sakamoto S; Yamada Y; Sugiura M; Rii J; Takeuchi N; Imamura Y; Furihata T; Ando K; Higuchi K; Xu M; Sazuka T; Nakamura K; Kaneda A; Kanai Y; Kyprianou N; Ikehara Y; Anzai N; Ichikawa T Sci Rep; 2020 Jan; 10(1):1292. PubMed ID: 31992742 [TBL] [Abstract][Full Text] [Related]
9. JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells. Choi DW; Kim DK; Kanai Y; Wempe MF; Endou H; Kim JK Korean J Physiol Pharmacol; 2017 Nov; 21(6):599-607. PubMed ID: 29200902 [TBL] [Abstract][Full Text] [Related]
10. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation. Quan L; Ohgaki R; Hara S; Okuda S; Wei L; Okanishi H; Nagamori S; Endou H; Kanai Y J Exp Clin Cancer Res; 2020 Nov; 39(1):266. PubMed ID: 33256804 [TBL] [Abstract][Full Text] [Related]
11. Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells. Nishikubo K; Ohgaki R; Okanishi H; Okuda S; Xu M; Endou H; Kanai Y J Cell Mol Med; 2022 Oct; 26(20):5246-5256. PubMed ID: 36071551 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment. Yothaisong S; Dokduang H; Anzai N; Hayashi K; Namwat N; Yongvanit P; Sangkhamanon S; Jutabha P; Endou H; Loilome W Tumour Biol; 2017 Mar; 39(3):1010428317694545. PubMed ID: 28347255 [TBL] [Abstract][Full Text] [Related]
13. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model. Fukumoto S; Hanazono K; Fu DR; Endo Y; Kadosawa T; Iwano H; Uchide T Biochem Biophys Res Commun; 2013 Sep; 439(1):103-8. PubMed ID: 23954667 [TBL] [Abstract][Full Text] [Related]
14. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour. Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327 [TBL] [Abstract][Full Text] [Related]
15. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells. Yun DW; Lee SA; Park MG; Kim JS; Yu SK; Park MR; Kim SG; Oh JS; Kim CS; Kim HJ; Kim JS; Chun HS; Kanai Y; Endou H; Wempe MF; Kim DK J Pharmacol Sci; 2014; 124(2):208-17. PubMed ID: 24492461 [TBL] [Abstract][Full Text] [Related]
16. Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters. Otsuki H; Kimura T; Yamaga T; Kosaka T; Suehiro JI; Sakurai H Prostate; 2017 Feb; 77(2):222-233. PubMed ID: 27696482 [TBL] [Abstract][Full Text] [Related]
17. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1. Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917 [TBL] [Abstract][Full Text] [Related]
18. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity. Rii J; Sakamoto S; Mizokami A; Xu M; Fujimoto A; Saito S; Koike H; Tamura T; Arai T; Yamada Y; Goto Y; Sazuka T; Imamura Y; Suzuki K; Kanai Y; Anzai N; Ichikawa T Cancer Sci; 2024 Mar; 115(3):937-953. PubMed ID: 38186218 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma. Cormerais Y; Pagnuzzi-Boncompagni M; Schrötter S; Giuliano S; Tambutté E; Endou H; Wempe MF; Pagès G; Pouysségur J; Picco V J Cell Mol Med; 2019 Apr; 23(4):2711-2718. PubMed ID: 30784173 [TBL] [Abstract][Full Text] [Related]
20. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Kanai Y Pharmacol Ther; 2022 Feb; 230():107964. PubMed ID: 34390745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]